Indications
panzyga® - Intravenous Human Immunoglobulin
panzyga® is approved for use in a wide variety of clinical indications.
panzyga® is used across a wide range of clinical indications, offering proven experience and support to healthcare professionals, patients and caregivers.
Replacement therapy in adults, and children and adolescents (0-18 years) in:1
Primary immunodeficiency syndromes (PID) with impaired antibody production.
Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum immunoglobulin (Ig) G level of <4g/l.
Immunomodulation in adults, and children and adolescents (0-18 years) in:1
Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count
Guillain Barré syndrome (GBS)
Kawasaki disease (in conjunction with acetylsalicylic acid)
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Multifocal motor neuropathy (MMN)
Reference:
panzyga® - Summary of Product Characteristics
